AcquisitionsMay 4, 2026, 04:33 PM
Twist Bioscience Acquires Invenra's Antibody Platform; Q1 Revenue +19.3%
AI Summary
Twist Bioscience reported a 19.3% increase in Q1 2026 revenue to $110.7 million, alongside an increased net loss of $44.0 million. The company also announced a significant strategic move, acquiring a co-exclusive license to Invenra's B-Body bispecific antibody discovery platform for $20.0 million and making a $13.8 million equity investment in Invenra. Cash and cash equivalents saw a notable decrease during the period.
Key Highlights
- Acquired co-exclusive license to Invenra's B-Body bispecific antibody discovery platform.
- Total consideration for the license was $20.0 million, including $5.0 million cash and $15.0 million in common stock.
- Invested $13.8 million in Invenra Series B Preferred Stock, settled by issuing common stock.
- Q1 2026 revenue increased 19.3% to $110.7 million from $92.8 million year-over-year.
- Q1 2026 net loss increased to $44.0 million from $39.3 million year-over-year.
- DNA synthesis and protein solutions revenue was $53.3 million in Q1 2026.
- NGS applications revenue was $57.4 million in Q1 2026.
- Cash and cash equivalents decreased to $122.7 million from $183.0 million since September 30, 2025.